NCT03695835: NIRPA

A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.

Completed Last updated 22 July 2020

What this trial tests

trial testing Immunotherapeutic Agents in Adenocarcinoma in 27 participants. Completed in 17 June 2020.

Timeline

11 April 2018

Primary endpoint
8 July 2019

17 June 2020

Quick facts

Lead sponsor	Gary Onik MD
Status	Completed
Study type	OBSERVATIONAL
Enrollment	27
Start date	11 April 2018
Primary completion	8 July 2019
Estimated completion	17 June 2020
Sites	1 location across United States

Drugs / interventions tested

• Immunotherapeutic Agents — full drug profile →
• Ablation

Conditions studied

• Adenocarcinoma — all drugs for Adenocarcinoma →

Sponsor

Gary Onik MD — full company profile →

Who can join

19 and older, any sex, with Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A retrospective and prospective data collection study on 27 consecutive subjects with adenocarcinoma who were treated using the MyVaccx system by Dr. Gary Onik. Retrospective data were collected on the treatment with the immunotherapy system and prospective data will be collected as they are prospectively monitored through their normal standard of care for their original cancer.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy.
   Yin L, Li XY, Zhu LL, Chen GL, et al · · 2022 · cited 15× · PMID 36131929 · DOI 10.3389/fimmu.2022.965120
2. Postablation Immune Microenvironment: Synergy between Interventional Oncology and Immuno-oncology.
   Kim D, Erinjeri JP. · · 2019 · cited 15× · PMID 31680725 · DOI 10.1055/s-0039-1696704
3. An In Vitro Investigation into Cryoablation and Adjunctive Cryoablation/Chemotherapy Combination Therapy for the Treatment of Pancreatic Cancer Using the PANC-1 Cell Line.
   Baust JM, Santucci KL, Van Buskirk RG, Raijman I, et al · · 2022 · cited 13× · PMID 35203660 · DOI 10.3390/biomedicines10020450
4. The road to overcome pancreatic cancer: Where are we?
   Tirpe A, Streianu C, Isachesku E, Simon I, et al · · 2024 · cited 6× · PMID 39403527 · DOI 10.1016/j.heliyon.2024.e38196
5. <i>In-situ</i> tumor vaccination by percutaneous ablative therapy and its synergy with immunotherapeutics: An update on combination therapy.
   Kim NJ, Yoon JH, Tuomi AC, Lee J, et al · · 2023 · cited 6× · PMID 36969248 · DOI 10.3389/fimmu.2023.1118845
6. First-in-Human Phase II Clinical Trial of Multiplex IntraTumoral Immunotherapy (MITI) in Patients with Metastatic Solid Cancer (Abscopal 5001 Trial).
   Bostwick DG, Wilk MM, Bostwick BR, Miller N, et al · · 2025 · PMID 41008834 · DOI 10.3390/cancers17182990